

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	9403070
<b>Application Number:</b>	10534348
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4929
<b>Title of Invention:</b>	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
<b>First Named Inventor/Applicant Name:</b>	Karen Silence
<b>Customer Number:</b>	23628
<b>Filer:</b>	Erik J. Spek/Eileen Flaherty
<b>Filer Authorized By:</b>	Erik J. Spek
<b>Attorney Docket Number:</b>	A0848.70005US00
<b>Receipt Date:</b>	08-FEB-2011
<b>Filing Date:</b>	09-MAY-2005
<b>Time Stamp:</b>	19:15:23
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Third_Party_Observations_data_06172009_Munich.pdf	138483 60ececbbb9676174d2c9684887275b7a622d09570	no	3

### Warnings:

### Information:

2	NPL Documents	Third_Party_Observations_dated_09012009_Barcelona.pdf	125817	no	4
			f18282df94cbdf375407d551dec646375eab4665		
Warnings:					
Information:					
3	NPL Documents	Third_Party_Observations_dated_09042009_Paris.pdf	246596	no	4
			5407c8de6072b7e5969e9863ccd10485a8c3f694		
Warnings:					
Information:					
4	NPL Documents	Summary_of_telephone_consultation_submitted_09252009.pdf	26793	no	1
			117fc8af078c45762bec95e86aefac4afddcc7c		
Warnings:					
Information:					
5	NPL Documents	Letter_of_Opponent_re_Opp_Proc_dated_09252009.pdf	190208	no	4
			4239a4384416c36d938c7d6cddc78dd9e9d0fbaf		
Warnings:					
Information:					
6	NPL Documents	Letter_of_Opponent_re_Opp_Proc_dated_12102009.pdf	1749312	no	34
			72dea95c99a63dc7899ebc68fd26dcdf3bc42acf		
Warnings:					
Information:					
7	NPL Documents	Decision_Revoking_European_Patent_EP_1517921_dated_04082010.pdf	69724	no	4
			756cd8bec7b2d1aa360dd70d838da5f743ba0a10c		
Warnings:					
Information:					
8	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_04082010.pdf	426703	no	10
			d932ba064d773c558071cdcae7dbb7dd931c744f		
Warnings:					
Information:					
9	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_Opposition_04082010.pdf	310856	no	8
			727a5d1d4106ce577377ef63d98a802f8de6a61		
Warnings:					
Information:					
10	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_Opposition_Grounds_for_Decision_to_Revok_e_04082010.pdf	1097502	no	17
			7348ff1e8dc420a79fa078caaec596501ec40031		
Warnings:					
Information:					

11	NPL Documents	Main_Request_filed_by_Patentee_07302010.pdf	104553	no	3
			66eff6dae65bfe1082df2fd5a59e037a93441bd8		
Warnings:					
Information:					
12	NPL Documents	Aux_Request1_filed_by_Patentee_07302010.pdf	112024	no	4
			f742a97ab5219d51ff46d73f11e16cd1fc79378d		
Warnings:					
Information:					
13	NPL Documents	Aux_Request2_filed_by_Patentee_07302010.pdf	130236	no	4
			65c3886beb4f33243db3dfc10788789a80634384		
Warnings:					
Information:					
14	NPL Documents	Aux_Request3_filed_by_Patentee_07302010.pdf	119187	no	4
			403a1d40e1a5071bc14b2887b15d8726dcf27433		
Warnings:					
Information:					
15	NPL Documents	Statement_of_grounds_of_appeal_filed_by_patentee_07302010.pdf	1334355	no	29
			e5bde64bef1adbd1547f9b37e3d5134b24a355b3		
Warnings:					
Information:					
16	NPL Documents	Barrios_et_al_J_Mol_Recog_2004_v17_p332.pdf	655949	no	7
			a4943bbbae9529eaf91434a5cda0566e70bd9907		
Warnings:					
Information:					
17	NPL Documents	Birkett_Ch_3_Pharmacokinetics_Made_Easy_1998_p16.pdf	9203432	no	11
			11bc92e0c564412984436a94edd240ff38743b71		
Warnings:					
Information:					
18	NPL Documents	Cheong_et_al_BiochemBiophysicalResComm_1990_v173_p795.pdf	272541	no	6
			9881e613b29a573e71cb0e5fc2647a455d12f8e2		
Warnings:					
Information:					
19	NPL Documents	Baniyash_et_al_EurJImmunol_1984_v14_p799.pdf	15685363	no	9
			935a0396cccd7688431223837d3f73666710431b		
Warnings:					
Information:					

20	NPL Documents	Chen_et_al_NuclAcidsRes_2002_v30_p412.pdf	474644	no	4
			8495a3bf1f5b2caffed9fee7904c2d72686ff239		
Warnings:					
Information:					
21	NPL Documents	Chuang_et_al_PharmaceutRes_2002_v19_p569.pdf	965941	no	9
			09db4ea7f8166fd5b2dacd999e1f2741548ec629		
Warnings:					
Information:					
22	NPL Documents	Cochran_et_al_JImmunolMethods_2004_v287_p147.pdf	1608376	no	12
			6a0514da4745dc01e8994f250d03dde5235fe3b		
Warnings:					
Information:					
23	NPL Documents	Connelly_InnPharmTechnol_2005_p42.pdf	532556	no	5
			eac99427f8a30675ac17ac81a77968e95c6642d1		
Warnings:					
Information:					
24	NPL Documents	Conrath_et_al_AntimicrobAgentsChemother_2001_v45_p2807.pdf	163966	no	6
			5bf99827d6a9afe59e2610a63b044be536e352ba		
Warnings:					
Information:					
25	NPL Documents	Crombet-Ramos_et_al_IntJCancer_2002_v101_p567.pdf	2229893	no	9
			a2dac719b40dc0581946e97b0591af0fb61e573b		
Warnings:					
Information:					
26	NPL Documents	Davies_et al_FEBS_Letts_1994_v339_p285.pdf	9383520	no	6
			b186eea6de7da003a1f0b12ee2efdf80e2a4ac5		
Warnings:					
Information:					
27	NPL Documents	Dennis_et_al_JBiologChem_2002_v277_p35035.pdf	294320	no	9
			b6a3e85b5c1a18427c44aa2fe4a8f1398ac1ec2e		
Warnings:					
Information:					
28	NPL Documents	Desmyter_et_al_JBiolChem_2002_v277_p23645.pdf	468491	no	6
			c0773272ea3df07930f22e157f7a36e45f4345f0		
Warnings:					
Information:					

29	NPL Documents	Dolk_et_al_Appl_Environ_Microbiol_2005_v71_p442.pdf	837292	no	9
			1e65bd04d475dbb35599ee2ffcec1a146452ba52		
Warnings:					
Information:					
30	NPL Documents	Drejer_et_al_Diabetes_1991_v40_p1488.pdf	720175	no	8
			af88e4f5ea2465d5dc8f82c02128f46a8c31df08		
Warnings:					
Information:					
31	NPL Documents	Dubnovitsky_et_al_Biochem_2000_v65_p1011.pdf	111201	no	8
			5f1a407972f379402ab001a085e29ecf76d9d4f4		
Warnings:					
Information:					
32	NPL Documents	Fahrner_et_al_BiotechnolGenEngineeringRev_2001_v18_p301.pdf	1311403	no	30
			aa91d439001047e75df6315fb38fcdc6245cd036a		
Warnings:					
Information:					
33	NPL Documents	Frenken_JBiotechnol_2000_v78_p11.pdf	802510	no	11
			3d242abe361c08bd9b14230e0f6738b20402e4a2		
Warnings:					
Information:					
34	NPL Documents	Hamilton-Wessler_et_al_Diabetologia_1999_v42_p1254.pdf	676308	no	10
			c15239ea4ed59d9ef51a0a29c144141087e2b742		
Warnings:					
Information:					
35	NPL Documents	Harmsen_et_al_VetMicrobiol_2005_v111_p89.pdf	740434	no	10
			45dfac447560ca385ac4f431f905fa78ceca162		
Warnings:					
Information:					
36	NPL Documents	Heitner_et_al_JImmunolMethods_2001_v248_p17.pdf	792566	no	14
			ac63a8269aa3fc3415bb5aff41f8e80f86f48367		
Warnings:					
Information:					
37	NPL Documents	Hey_et_al_TrendsBiotechnol_2005_v23_p514.pdf	895951	no	9
			f0bd0ed79f39ef22ff599abc389b3b856b9086c		
Warnings:					
Information:					

38	NPL Documents	Holliger_et_al_Nature_Biotech_1997_v15_p632.pdf	1520751	no	5
			a26b0dece1fd156535be7ef280a18bbafcd51b8		
Warnings:					
Information:					
39	NPL Documents	Holt_et_al_TrendsInBiotech_2003_v21_p484.pdf	938229	no	8
			1daa6a01c4e34e7e693ee39d391d2fd0b5b3a3		
Warnings:					
Information:					
40	NPL Documents	Hoogenboom_et_al_Nature_Biotech_1997_v15_p125.pdf	418328	no	2
			8d2f4049e052b7200c77293af78eabae109a2746		
Warnings:					
Information:					
41	NPL Documents	Hulme_et_al_Proc_R_Soc_Med_1966_v59_p509.pdf	551823	no	4
			9216083d9fb285fb1eadb2c890dd8d6e8548d49d		
Warnings:					
Information:					
42	NPL Documents	Janeway_et_al_Immunobiology_1997_3rd_ed_part2_p31.pdf	1360227	no	14
			3050f6441dc26a7cbcf24b6e8856254f91da21		
Warnings:					
Information:					
43	NPL Documents	Janeway_et_al_Immunobiol_1997_219-220.pdf	306387	no	5
			3f06ed1f52057e031847a32d72a3d841c69409eb		
Warnings:					
Information:					
44	NPL Documents	Kang_et_al_EPJCancer_v38_pS149_PosterSessions.pdf	103226	no	1
			d1433c94af239ed90abad4dbe1e24a96884637aa		
Warnings:					
Information:					
45	NPL Documents	King_ApplicationsandEngineofMonoclonalAntibodies_1998_p40.pdf	2380490	no	13
			8226d2ada4db3fefe040a63064386432aac88567		
Warnings:					
Information:					
46	NPL Documents	Kruger_et_al_ApplMicrobiolBiotechnol_2006_v72_p732.pdf	144110	no	6
			ed1abcbfdac1993976e8e10deb885d579cc5e7c		
Warnings:					
Information:					

47	NPL Documents	Lauwereys_et_al_EMBOJ_1998_v17_p3512.pdf	457436	no	9
			f55213a75cc2ca9534e79c9501983670d4d25677		
Warnings:					
Information:					
48	NPL Documents	MacEwan_et_al_BrJPharmacol_2002_v135_p855.pdf	1982342	no	21
			e39fe7a21558b1850a6d1fd625d8354a0cae331		
Warnings:					
Information:					
49	NPL Documents	Mamot_et_al_CancerRes_2003_v63_p3154.pdf	684848	no	8
			242f14eb301b33a6c065f0fe8d7de31ccb5bad5b		
Warnings:					
Information:					
50	NPL Documents	Mauri_et_al_JExpMed_2003_v197_p489.pdf	1039098	no	13
			b4ba66ad56e8867b8209acd8556203765a892fbc		
Warnings:					
Information:					
51	NPL Documents	Morelli_et_al_CancerRes_1996_v56_p2082.pdf	881961	no	4
			261d6832632993a77a4622790b6a6ebe78008d22		
Warnings:					
Information:					
52	NPL Documents	Muyldermans_et_al_TrendsBiochemSci_2001_v26_p230.pdf	552949	no	6
			14e3a262cc7323436dddb2306d57866fb4c4a6f		
Warnings:					
Information:					
53	NPL Documents	Muyldermans_et_al_JMolRecongnit_1999_v12_p131.pdf	1095524	no	11
			66d511287003017d1e211b02a42b4c8a3585dd0c		
Warnings:					
Information:					
54	NPL Documents	Nilsson_et_al_ProteinExpandPurification_1997_v11_p1.pdf	1140820	no	16
			04768fcd29faa2f256864fb356b3a60ce3a2cbb		
Warnings:					
Information:					
55	NPL Documents	Nygren_et_al_Vaccines_1991_v91_p363.pdf	248615	no	6
			14cf5ca4cb682f9d50ec6d8c9e7fbc0f7fada5ce		
Warnings:					
Information:					

56	NPL Documents	Pant_et_al_JInfectDis_2006_v194_p1580.pdf	1334383 09d61845127e4f1ead92b58b1eb6d6e9b3d40d67	no	9
Warnings:					
Information:					
57	NPL Documents	Presta_et_al_ThrombHaemost_2001_v85_p379.pdf	1034603 e19ea9ac02a0dddc8027354374badba0264bfff775	no	11
Warnings:					
Information:					
58	NPL Documents	Reilly_et_al_ClinPharmacokinet_1997_v32_p313.pdf	1481098 40611efbd78ca7a32fc34a7d78cf0fb18e775129	no	11
Warnings:					
Information:					
59	NPL Documents	Miyajima_et_al_IntArchAllergylmmunol_2002_v128_p24.pdf	683029 779498dcd3699bac33ca6224ed8c2b36af031fe4	no	9
Warnings:					
Information:					
60	NPL Documents	Reeck_et_al_Cell_1987_v50_p667.pdf	257181 18c1450a4fc289151c5864369d6793fab481bee8	no	1
Warnings:					
Information:					
Total Files Size (in bytes):			75606639		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					